Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Cabaletta Bio receives FDA IND clearance to initiate first-in-human study of DSG3-CAART

Oct. 2, 2019

AnaptysBio reports phase II interim data on ANB-019 in generalized pustular psoriasis

Oct. 1, 2019

Pfizer announces topline results from pivotal JADE MONO-2 study of abrocitinib

Sep. 30, 2019

First patient dosed in phase III TRuE-V clinical trial program of ruxolitinib cream

Sep. 26, 2019

Galapagos initiates phase I trial with GLPG-3970

Sep. 26, 2019

Phase III study of StrataGraft regenerative tissue meets both primary endpoints

Sep. 25, 2019

Bristol-Myers Squibb designs RORgammaT inverse agonists showing biologic-like efficacy

Sep. 9, 2019

Krystal Biotech initiates phase I/II study of topical KB-105 gene therapy for TGM1-deficient ARCI

Sep. 2, 2019

Phase III BREEZE-AD7 study of baricitinib in atopic dermatitis meets primary endpoint

Aug. 26, 2019

Bruton tyrosine kinase inhibitors discovered at Merck & Co.

Aug. 22, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...